

Tsuyoshi Ohta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4702945/publications.pdf>

Version: 2024-02-01

18
papers

365
citations

1040056

9
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

682
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of Phosphatidylinositol 3-Kinase Increases Efficacy of Cisplatin in in Vivo Ovarian Cancer Models. <i>Endocrinology</i> , 2006, 147, 1761-1769.	2.8	78
2	Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patients report for 2015 and annual treatment report for 2010. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 289-298.	1.3	54
3	Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1 α in human ovarian cancer cells. <i>Cancer Biology and Therapy</i> , 2012, 13, 25-33.	3.4	50
4	xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma. <i>Oncology Letters</i> , 2020, 20, 2689-2700.	1.8	34
5	Annual report of the <scp>Committee on Gynecologic Oncology</scp>, the <scp>Japan Society of Obstetrics and Gynecology</scp>: Annual patient report for 2017 and annual treatment report for 2012. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 1631-1642.	1.3	32
6	Activation of estrogen receptor β by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells. <i>Cancer Biology and Therapy</i> , 2017, 18, 730-739.	3.4	20
7	Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells. <i>Cancer Biology and Therapy</i> , 2012, 13, 408-416.	3.4	18
8	The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome. <i>Anticancer Research</i> , 2009, 29, 4639-47.	1.1	15
9	Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2018 and Annual Treatment Report for 2013. <i>Journal of Obstetrics and Gynaecology Research</i> , 2022, 48, 541-552.	1.3	12
10	Clinical and reproductive outcomes of fertility-sparing surgery in stage I epithelial ovarian cancer. <i>Molecular and Clinical Oncology</i> , 2020, 12, 44-50.	1.0	9
11	The Wilms' Tumor Gene WT1 α 17AA KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model. <i>Translational Oncology</i> , 2014, 7, 580-589.	3.7	8
12	Successful management of cutaneous lymphangitis carcinomatosa arising from cervical cancer with paclitaxel-cisplatin and bevacizumab combination therapy: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2019, 13, 328.	0.8	7
13	Squamous cell carcinoma arising from a mature cystic teratoma of the ovary: Successful treatment with carboplatin, paclitaxel, and bevacizumab. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100632.	0.6	7
14	Characteristic features of ovarian borderline tumors with invasive implant. <i>Archives of Gynecology and Obstetrics</i> , 2005, 272, 278-282.	1.7	6
15	A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study). <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 355-361.	2.3	6
16	Tumor lysis syndrome associated with docetaxel and carboplatin in a case with recurrent endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2018, 24, 21-23.	0.6	6
17	Surveillance of radical hysterectomy for early-stage cervical cancer in the early experienced period of minimally invasive surgery in Japan. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2318-2330.	2.2	3
18	Nuclear receptor coactivator β is essential for the morphological change of human uterine stromal cell decidualization via regulating actin fiber reorganization. <i>Molecular Reproduction and Development</i> , 2022, , .	2.0	0